BG108435A - Нови кристални форми на 4-[4-[4-хидроксидифенилметил)-1-пиперидинил]-1-хидроксибутил]-алфа,алфа-диметилбензеноцетна киселина и на нейния хидрохлорид - Google Patents

Нови кристални форми на 4-[4-[4-хидроксидифенилметил)-1-пиперидинил]-1-хидроксибутил]-алфа,алфа-диметилбензеноцетна киселина и на нейния хидрохлорид

Info

Publication number
BG108435A
BG108435A BG108435A BG10843503A BG108435A BG 108435 A BG108435 A BG 108435A BG 108435 A BG108435 A BG 108435A BG 10843503 A BG10843503 A BG 10843503A BG 108435 A BG108435 A BG 108435A
Authority
BG
Bulgaria
Prior art keywords
alpha
hydrochloride
hydroxybutyl
piperidinyl
acetic acid
Prior art date
Application number
BG108435A
Other languages
English (en)
Inventor
Reddy SATYANARAYANA
Rajan Thirumalai
Rao Bhaskara
Original Assignee
Dr. Reddy's Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of BG108435A publication Critical patent/BG108435A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретението се отнася до нова полиморфна форма на фексофенадин и фексофенадин хидрохлорид с формула и до метод за нейното получаване. Изобретението се отнася и до получаване на нови полиморфни форми на фексофенадин и на неговия хидрохлорид чрез опростен метод, който е икономически изгоден и е благоприятен за околната среда. а
BG108435A 2001-06-18 2003-12-11 Нови кристални форми на 4-[4-[4-хидроксидифенилметил)-1-пиперидинил]-1-хидроксибутил]-алфа,алфа-диметилбензеноцетна киселина и на нейния хидрохлорид BG108435A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN484MA2001 2001-06-18

Publications (1)

Publication Number Publication Date
BG108435A true BG108435A (bg) 2004-12-30

Family

ID=34566868

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108435A BG108435A (bg) 2001-06-18 2003-12-11 Нови кристални форми на 4-[4-[4-хидроксидифенилметил)-1-пиперидинил]-1-хидроксибутил]-алфа,алфа-диметилбензеноцетна киселина и на нейния хидрохлорид

Country Status (20)

Country Link
EP (2) EP2261209A1 (bg)
JP (2) JP2005507374A (bg)
KR (1) KR20040015734A (bg)
CN (1) CN100390145C (bg)
AU (1) AU2001278094B2 (bg)
BG (1) BG108435A (bg)
BR (1) BR0117054A (bg)
CA (2) CA2646802A1 (bg)
CO (1) CO5540340A2 (bg)
CZ (1) CZ20033358A3 (bg)
EE (1) EE200400010A (bg)
HU (1) HUP0401546A2 (bg)
IL (2) IL159266A0 (bg)
MX (1) MXPA03011728A (bg)
NZ (1) NZ530118A (bg)
PL (1) PL367632A1 (bg)
RU (1) RU2269516C2 (bg)
SK (1) SK15372003A3 (bg)
WO (1) WO2002102777A2 (bg)
ZA (1) ZA200309557B (bg)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392303A4 (en) * 2001-04-09 2005-01-26 Teva Pharma FEXOFENADINE HYDROCHLORIDE POLYMORPHS
JP2005532356A (ja) * 2002-06-10 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド 塩酸フェキソフェナジンの多型体ｘｖｉ
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
MXPA06012281A (es) * 2004-04-26 2007-07-18 Teva Pharma Formas cristalinas de clorhidrato de fexofenadina y procesos para su preparacion.
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
WO2006037042A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
WO2007007347A1 (en) * 2005-07-07 2007-01-18 Wockhardt Limited Industrial process of fexofenadine hydrochloride with controlled side products
EP2105134A1 (en) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stable amorphous fexofenadine hydrochloride
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
WO1995031437A1 (en) * 1994-05-18 1995-11-23 Hoechst Marrion Roussel, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
IN191492B (bg) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
GB0018691D0 (en) * 2000-07-28 2000-09-20 Rolabo Sl Process

Also Published As

Publication number Publication date
WO2002102777A3 (en) 2003-02-27
KR20040015734A (ko) 2004-02-19
JP2005507374A (ja) 2005-03-17
CN100390145C (zh) 2008-05-28
PL367632A1 (en) 2005-03-07
CZ20033358A3 (en) 2004-04-14
CA2450858C (en) 2009-04-07
SK15372003A3 (sk) 2004-08-03
CA2646802A1 (en) 2002-12-27
CO5540340A2 (es) 2005-07-29
WO2002102777A2 (en) 2002-12-27
ZA200309557B (en) 2004-09-14
EP1399422A2 (en) 2004-03-24
JP2008094848A (ja) 2008-04-24
IL159266A (en) 2010-11-30
CN1518540A (zh) 2004-08-04
EE200400010A (et) 2004-02-16
NZ530118A (en) 2007-05-31
HUP0401546A2 (hu) 2004-12-28
MXPA03011728A (es) 2004-07-08
RU2004101045A (ru) 2005-06-27
EP2261209A1 (en) 2010-12-15
WO2002102777A8 (en) 2003-10-30
IL159266A0 (en) 2004-06-01
CA2450858A1 (en) 2002-12-27
AU2001278094B2 (en) 2006-01-12
BR0117054A (pt) 2004-07-27
RU2269516C2 (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
BG108435A (bg) Нови кристални форми на 4-[4-[4-хидроксидифенилметил)-1-пиперидинил]-1-хидроксибутил]-алфа,алфа-диметилбензеноцетна киселина и на нейния хидрохлорид
DK153709B (da) Analogifremgangsmaade til fremstilling af 4-substituerede piperidinoalkanolderivater
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
SK145894A3 (en) Vinegar acid derivatives, method of their production, pharmaceutical agents on their base and their using
NO162819B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenyleddiksyrederivater.
TW200734038A (en) Novel dispersant and compositions thereof
JP2009533369A5 (bg)
AU2005272389A1 (en) Novel cyclic aminobenzoic acid derivative
CA2584833A1 (en) Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines
IL180192A (en) The result of arylamide, its salt and the antifungals that contain them
US5166148A (en) 2-amino-1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
JP5673729B2 (ja) ４−置換又は非置換テトラヒドロピラン−４−カルボン酸化合物又はそのエステル化合物の製法
JP2010536713A5 (bg)
CA2429563C (en) Process for the preparation of donepezil
NO20082474L (no) Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav
JP5585822B2 (ja) 光学活性ニペコチン酸誘導体の製造方法
NZ598718A (en) Polymorphic forms of manidipine
TW200637856A (en) Process for producing thiazolidinedion compound and intermediate thereof
DK1489080T3 (da) Fremgangsmåde til frembringelse af cilostazol
PL353977A1 (en) Method of obtaining 4-[1-hydroxy-4-[4-(hydroxydiphenyldimethyl)-1-piperidinylbutyl]-alpha,alpha-dimethylbenzene acetic acid
AU2008288430A1 (en) Novel preparation process
WO2006013049A3 (en) Benzyloxy derivatives as maob inhibitors
WO2005076749A3 (en) A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
WO2009084030A3 (en) Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii
US20110295000A1 (en) Production method